Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab With and Without Nivolumab in Relapsed/Refractory Classic Hodgkin Lymphoma
NCT04938232Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in Hodgkin lymphoma (HL), sponsored by Dana-Farber Cancer Institute. Started Jun 2021; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04938232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938232.